The Takeda/Shire merger will catapult the new company to the “top 10” pharma list, but greater size brings greater challenges, including manufacturing glitches and review issues. Explore the challenges each company brought to the merger and the new ones the merged faces today.
Author: Bridget Silverman
Published: 16 May 2018
Number of pages:4
Takeda’s acquisition of Shire–perhaps better characterized as a merger–is already transforming the pharma landscape. As is often the case, however, the first year of marriage can be rocky. Challenges abound, including manufacturing glitches and an array of review and development issues. The merged company is poised to become a market leader in rare diseases and plasma derivatives. It is expected to have roughly $30 billion in revenues and will join the ranks of the top 10 drugmakers. Still, nagging questions remain: Will the U.S. FDA approve lanadelumab?
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.